To Investigate the Effect of Rosiglitazone and Ramipril on Pre-clinical Vasculopathy in Diabetes and IGT Patients

Summary

The aim is to examine whether pharmacological interventions with thiazolidinedione and angiotensin converting enzyme (ACE) inhibitors can reverse pre-clinical vasculopathy in newly diagnosed diabetic and IGT individuals.

Timeline

Start

2002-10

Primary completion

—

Completion

2005-12

Outcome

Missed primary endpoint

paper however, these differences were not significant in comparison to placebo. PMID 22291490 ↗

paper standard doses of rosiglitazone and ramipril are not adequate to reverse pre-clinical vasculopathy in T2DM. PMID 22291490 ↗

Publications

• Rahman S, Ismail AA, Ismail SB, Naing NN, Rahman AR. Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses? Clin Pharmacol. 2010;2:83-7. doi: 10.2147/CPAA.S8863. Epub 2010 Apr 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ramipril	Small molecule	5 mg	—
Subject	Rosiglitazone	Small molecule	4 mg	—

Indications